NASDAQ:AGRX
Agile Therapeutics Stock News
$0.400
+0 (+0%)
At Close: Apr 26, 2024
Recap: Agile Therapeutics Q1 Earnings
05:24pm, Tuesday, 04'th May 2021
Shares of Agile Therapeutics (NASDAQ:AGRX) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 100.00% year over year to ($0.20), which b
Agile Therapeutics Reports First Quarter 2021 Financial Results
04:05pm, Tuesday, 04'th May 2021
Prescription Growth Reflects Increasing Demand for Twirla
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evalua
CORRECTING AND REPLACING -- Agile Therapeutics
10:56am, Tuesday, 20'th Apr 2021
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report Fir
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
09:30am, Tuesday, 20'th Apr 2021
Live Conference Call and Webcast at 4:30 p.m. EDT Live Conference Call and Webcast at 4:30 p.m. EDT
7 Beaten Down Stocks with Significant Insider Buying
02:16pm, Friday, 09'th Apr 2021
Insider buying could be a bullish sign for a stock. Insiders may sell their shares for many reasons.
Agile Therapeutics to Present at Upcoming March Investor Conferences
07:30am, Friday, 05'th Mar 2021
PRINCETON, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairman and Chief Executive Officer Al Altomari will p
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q4 2020 Results - Earnings Call Transcript
10:45pm, Monday, 01'st Mar 2021
Agile Therapeutics, Inc. (AGRX) CEO Alfred Altomari on Q4 2020 Results - Earnings Call Transcript
Agile Therapeutics (AGRX) Reports Q4 Loss, Misses Revenue Estimates
06:57pm, Monday, 01'st Mar 2021
Agile Therapeutics (AGRX) delivered earnings and revenue surprises of 13.04% and -25.84%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Agile Therapeutics Reports Fourth Quarter & Full Year 2020 Financial Results; Expands Loan Facility With Perceptive Advisors
04:05pm, Monday, 01'st Mar 2021
Perceptive Advisors Increases Credit Facility to $45 million, with $25 million potentially available
Live Conference Call and Webcast at 4:30 p.m. ET
Agile Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference
12:18pm, Monday, 04'th Jan 2021
PRINCETON, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced Chairman and Chief Executive Officer Al Altomari will partici
Agile Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
07:30am, Monday, 21'st Dec 2020
PRINCETON, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced the Company will present at the 39th Annual J.P. Morgan Healt
Agile Therapeutics: Managing A Position Ahead Of Twirla's Launch
01:47pm, Monday, 07'th Dec 2020
Agile Therapeutics is preparing to launch their first FDA approved product, Twirla. If all goes well, Twirla could quickly establish a foothold in a $4.1B addressable market. Launching an FDA approved
